Co-Authors
This is a "connection" page, showing publications co-authored by Guangdi Wang and Qian-Jin Zhang.
Connection Strength
3.647
-
Zhang Q, Ma P, Cole RB, Wang G. In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes. Eur J Pharm Sci. 2010 Sep 11; 41(1):163-72.
Score: 0.373
-
Zhang Q, Ma P, Cole RB, Wang G. Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal Bioanal Chem. 2006 Nov; 386(5):1345-55.
Score: 0.288
-
Zhang Q, Ma P, Wang W, Cole RB, Wang G. In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands. Drug Metab Dispos. 2005 Apr; 33(4):508-17.
Score: 0.256
-
Zhang Q, Ma P, Wang W, Cole RB, Wang G. Characterization of rat liver microsomal metabolites of AM-630, a potent cannabinoid receptor antagonist, by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2004 Jun; 39(6):672-81.
Score: 0.246
-
Zhang Q, Ma P, Iszard M, Cole RB, Wang W, Wang G. In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab Dispos. 2002 Oct; 30(10):1077-86.
Score: 0.219
-
Zhang C, Guo S, Zhong Q, Zhang Q, Hossain A, Zheng S, Wang G. Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability. Pharmaceuticals (Basel). 2019 Dec 08; 12(4).
Score: 0.180
-
Zheng S, Guo S, Zhong Q, Zhang C, Liu J, Yang L, Zhang Q, Wang G. Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Med Chem Lett. 2018 Feb 08; 9(2):149-154.
Score: 0.158
-
Zhang C, Guo S, Yang L, Liu J, Zheng S, Zhong Q, Zhang Q, Wang G. Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD). Oncotarget. 2017 Nov 28; 8(61):103874-103889.
Score: 0.155
-
Liu J, Zheng S, Guo S, Zhang C, Zhong Q, Zhang Q, Ma P, Skripnikova EV, Bratton MR, Wiese TE, Wang G. Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator. ACS Med Chem Lett. 2017 Jan 12; 8(1):102-106.
Score: 0.146
-
Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD). J Med Chem. 2016 09 08; 59(17):8134-40.
Score: 0.144
-
Du F, Li Y, Zhang W, Kale SP, McFerrin H, Davenport I, Wang G, Skripnikova E, Li XL, Bowen NJ, McDaniels LB, Meng YX, Polk P, Liu YY, Zhang QJ. Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression. Tumour Biol. 2016 Aug; 37(8):11147-11162.
Score: 0.139
-
Zhong Q, Zhang C, Zhang Q, Miele L, Zheng S, Wang G. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. BMC Cancer. 2015 Sep 09; 15:625.
Score: 0.134
-
Zhang C, Zhong Q, Zhang Q, Zheng S, Miele L, Wang G. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer. Breast Cancer Res Treat. 2015 Jul; 152(2):283-91.
Score: 0.132
-
Zheng S, Zhong Q, Xi Y, Mottamal M, Zhang Q, Schroeder RL, Sridhar J, He L, McFerrin H, Wang G. Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. J Med Chem. 2014 Aug 14; 57(15):6653-67.
Score: 0.124
-
Zheng S, Zhong Q, Mottamal M, Zhang Q, Zhang C, Lemelle E, McFerrin H, Wang G. Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents. J Med Chem. 2014 Apr 24; 57(8):3369-81.
Score: 0.122
-
Tilghman SL, Townley I, Zhong Q, Carriere PP, Zou J, Llopis SD, Preyan LC, Williams CC, Skripnikova E, Bratton MR, Zhang Q, Wang G. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics. 2013 Sep; 12(9):2440-55.
Score: 0.114
-
Zheng S, Zhong Q, Jiang Q, Mottamal M, Zhang Q, Zhu N, Burow ME, Worthylake RA, Wang G. Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion. ACS Med Chem Lett. 2013 Feb 14; 4(2):191-196.
Score: 0.112
-
Jiang Q, Zhong Q, Zhang Q, Zheng S, Wang G. Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer. ACS Med Chem Lett. 2012 Apr 06; 3(5):392-396.
Score: 0.106
-
Wang G, Ma P, Zhang Q, Lewis J, Lacey M, Furukawa Y, O'Reilly SE, Meaux S, McLachlan J, Zhang S. Endocrine disrupting chemicals in New Orleans surface waters and Mississippi Sound sediments. J Environ Monit. 2012 May; 14(5):1353-64.
Score: 0.106
-
Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, Wang G. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012 Mar 14; 14(2):R45.
Score: 0.105
-
Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, Wang G. Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26; 53(16):6153-63.
Score: 0.095
-
Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res. 2008; 10(6):R105.
Score: 0.084
-
Kang B, Mottamal M, Zhong Q, Bratton M, Zhang C, Guo S, Hossain A, Ma P, Zhang Q, Wang G, Payton-Stewart F. Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer. Pharmaceuticals (Basel). 2023 May 12; 16(5).
Score: 0.057
-
Washington C, Maxwell J, Stevenson J, Malone G, Lowe EW, Zhang Q, Wang G, McIntyre NR. Mechanistic studies of the tyrosinase-catalyzed oxidative cyclocondensation of 2-aminophenol to 2-aminophenoxazin-3-one. Arch Biochem Biophys. 2015 Jul; 577-578:24-34.
Score: 0.033
-
Huang TL, Bacchi CJ, Kode NR, Zhang Q, Wang G, Yartlet N, Rattendi D, Londono I, Mazumder L, Vanden Eynde JJ, Mayence A, Donkor IO. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug. Int J Antimicrob Agents. 2007 Dec; 30(6):555-61.
Score: 0.019